TNF and tuberculosis: These findings indicate that in vivo administration of TNF antagonists decreases the number of anti-TB CD4+ T lymphocytes immediately releasing IFN-γ in response to mycobacterial antigens, whereas this treatment does not affect proliferative responses to the same antigens.